Ulcerative colitis trials in Germany

In Germany 38 Also abroad 381

38 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
Where
Augsburg, Berlin, Brandenburg An Der Havel, Duisburg, Frankfurt Am Main, Halle (Saale), Hamburg, Hanover, Kiel, Munich, Remscheid, Ulm
Age
18 years and over
People
587 worldwide
Run by
Eli Lilly & Co.
See details and how to join2023-507853-13-00 · EU 2023-507853-13-00
Phase 2Enrolling by invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Where
Berlin, Brandenburg An Der Havel, Bremen, Dachau, Frankfurt Am Main, Kiel, Leipzig, Munich, Tuebingen, Ulm
Age
18 years and over
People
645 worldwide
Run by
Spyre Therapeutics, Inc.
See details and how to joinNCT07652294 · EU 2025-524640-35-00
Phase 1Not yet taking people in Germany
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Where
Berlin, Cottbus, Munich, Ulm
Age
18 years to 65 years
People
25
Run by
Sanofi
See details and how to joinNCT07923383 · EU 2026-525939-17-00
Phase 3Taking people
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Where
Frankfurt, Grevenbroich, Halle, Hanover, Leipzig, Potsdam
Age
18 years to 70 years
People
350 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06937086 · EU 2024-520209-38-00
Phase 2Taking people
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Where
Berlin, Dachau, Erlangen, Regensburg, Ulm
Age
18 years to 80 years
People
252 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07186101
Phase 2Taking people
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Where
Berlin, Dachau, Halle (Saale), Ludwigshafen am Rhein, Ulm
Age
18 years to 80 years
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483073 · EU 2025-524112-11-00
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Hamburg, Sankt Augustin
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
No phaseTaking people
A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
Where
Berlin
Age
18 years and over
People
500
Run by
Janssen-Cilag G.m.b.H
See details and how to joinNCT07102368
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Where
Berlin, Dachau, Dresden, Erlangen, Frankfurt Am Main, Halle (Saale), Halle Saale, Hanover, Jena, Kassel, Kiel, Leipzig, Mannheim, Munich, Regensburg, Rostock, Ulm
Age
18 years and over
People
644 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577856 · EU 2026-525923-26-00
Phase 4Taking people
A study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indication
Where
Frankfurt
People
16 worldwide
Run by
Eli Lilly & Co.
See details and how to join2025-522362-78-00 · EU 2025-522362-78-00
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Where
Frankfurt Am Main, Regensburg
Age
18 years and over
People
224 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT06979336 · EU 2025-520690-39-00
Phase 2Taking people
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Where
Berlin, Brandenburg An Der Havel, Bremen, Dachau, Frankfurt Am Main, Kiel, Leipzig, Munich, Tuebingen, Ulm
Age
18 years to 75 years
People
645 worldwide
Run by
Spyre Therapeutics, Inc.
See details and how to joinNCT07012395 · EU 2025-521242-26-00
Phase 3Taking people
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Where
Cottbus, Erlangen, Kassel, Muenster, Potsdam
Age
2 years to 17 years
People
120 worldwide
Run by
AbbVie
See details and how to joinNCT07071519 · EU 2024-514695-41-00
Phase 3Taking people
A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis
Where
Aachen, Leipzig, Mainz, Tuebingen
Age
Up to 17 years
People
68 worldwide
Run by
Alfasigma S.p.A.
See details and how to join2024-511458-32-00 · EU 2024-511458-32-00
Phase 2Taking people
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
Where
Leipzig, Muenster, Tuebingen, Wuppertal
Age
2 years to 11 years
People
24 worldwide
Run by
Pfizer
See details and how to joinNCT07470879 · EU 2025-523100-77-00
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Where
Berlin, Halle, Herne, Kiel, Leipzig, Minden, Ulm, Wolfsburg
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184996
Phase 2Taking people
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Where
Brandenburg An Der Havel, Rostock, Ulm
Age
18 years to 75 years
People
100 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07463183 · EU 2025-523479-49-00
Phase 2/3Taking people
Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis
Where
Aachen, Augsburg, Bamberg, Berlin, Bremen, Cologne, Darmstadt, Dornstadt, Dresden, Frankfurt am Main, Frankfurt Am Main, Halle (Saale), Hamburg, Hamm, Hannover, Heidelberg, Kiel, Ludwigshafen am Rhein, Luebeck, Magdeburg, Mannheim, Muenster, Ulm
Age
18 years to 80 years
People
459
Run by
University Hospital Schleswig-Holstein
See details and how to joinNCT06488625 · EU 2024-510807-13-00
No phaseTaking people
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Where
Ahaus, Altenburg, Altenholz, Andernach, Berlin, Bochum, Buedelsdorf, Cologne, Dresden, Düsseldorf, Freiburg im Breisgau, Geesthacht, Halle, Hamburg, Hanover, Heide, Heidelberg, Herne, Jena, Jerichow, Karlsruhe, Kiel, Koblenz, Leipzig, Leverkusen, Lübeck, Ludwigshafen am Rhein, Magdeburg, Minden, Münster, Neumünster, Nordhausen, Pirmasens, Potsdam, Schwerin, Solingen, Teuchern, Tostedt, Wesseling, Witten, Wriezen, Würselen
Age
18 years and over
People
200
Run by
AbbVie
See details and how to joinNCT06764706
Phase 2/3Taking people
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Where
Dresden, Leipzig, München
Age
2 years to 17 years
People
120 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT05076175
Phase 3Taking people
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
Where
Aachen, Leipzig, Mainz, Tübingen
Age
8 years to 18 years
People
80 worldwide
Run by
Alfasigma S.p.A.
See details and how to joinNCT06865417
Phase 3Taking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Where
Berlin, Halle, Kiel, Leipzig, Minden, Tübingen, Ulm
Age
16 years to 80 years
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07185009
Phase 1Taking people
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
Where
Berlin
Age
18 years to 60 years
People
25 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07665723 · EU 2025-524060-38-00
Phase 2Taking people
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study
Where
Berlin, Dachau, Erlangen, Regensburg, Ulm
Age
18 years and over
People
75 worldwide
Run by
Eli Lilly & Co.
See details and how to join2025-522338-30-00 · EU 2025-522338-30-00
Phase 3Taking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
Mainz, Munich
Age
2 years to 19 years
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606